Omega Therapeutics, Inc.
OMGADelisted Mar 20, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850838
Omega Therapeutics, Inc. was delisted on Mar 20, 2025; its insiders filed their last Form 4 on Dec 5, 2024; 53 institutions reported holding it in 13F filings for Q4 2024, worth $35.3M in total; no superinvestor held it.
Q4 2024 vs. Q3 2024
How the institutions holding Omega Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 54 | 1 | 53 | 0 |
| Shares | 48.3M | 59.5K | 47.3M | −986.3K (−2.0%) |
| Value | $59.0M | $72.6K | $35.3M | −$23.6M (−40.1%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Omega Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 122,191 | $91.1K | 0.00% |
| Raymond James Financial Inc | 30,091 | $22.4K | 0.00% |
| Colony Group, LLC | 14,000 | $10.4K | 0.00% |
| Two Sigma Securities, LLC | 12,053 | $8.99K | 0.00% |
| HM Payson & Co | 2,500 | $1.86K | 0.00% |
| SBI Securities Co., Ltd. | 415 | $309 | 0.00% |
| BNP Paribas Arbitrage, SA | 235 | $175 | 0.00% |
| Capital A Wealth Management, LLC | 24 | $18 | 0.00% |
Sold out (8)
Institutions that held Omega Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Platinum Investment Management Ltd | 346,352 | $422.5K |
| Marex Group plc | 36,080 | $44.0K |
| XTX Topco Ltd | 32,253 | $39.3K |
| Squarepoint Ops LLC | 18,162 | $22.2K |
| Catalyst Funds Management Pty Ltd | 6,100 | $7.44K |
| Harbour Investments, Inc. | 275 | $336 |
| Advisor Group Holdings, Inc. | 200 | $244 |
| SRS Capital Advisors, Inc. | 54 | $66 |
Not filed for Q4 2024 yet (1)
Institutions that held Omega Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 59,474 | $72.6K |